Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs

NCT02993614 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02993614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02993614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
November 30, 2017
Completion date
December 17, 2020
Enrollment
99,999 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2